Ferroptosis:An emerging therapeutic opportunity for cancer

作     者：Liyuan Wang Xiaoguang Chen Chunhong Yan 

作者机构：Georgia Cancer CenterAugusta UniversityAugustaGA 30912USA Department of PharmacologyInstitute of Materia MedicaPeking Union Medical College and Chinese Academy of Medical SciencesBeijing 100050China Department of PharmacyPeking University Third HospitalBeijing 100191China Department of Biochemistry and Molecular BiologyMedical College of GeorgiaAugusta UniversityAugustaGA 30912USA 

出 版 物：《Genes & Diseases》 (基因与疾病（英文）)

年 卷 期：2022年第9卷第2期

页      面：334-346页

核心收录：

学科分类：0710[理学-生物学] 0831[工学-生物医学工程（可授工学、理学、医学学位）] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 0703[理学-化学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This work was supported by the National Institutes of Health grant(No.R01CA240966) the US Department of Defense award(No.W81XWH1910587 to CY) 

主　　题：Cancer therapy Erastin Ferroptosis GPX4 Lipid peroxidation Nanomedicine RSL3 System Xc- 

摘      要：Ferroptosis,a new form of non-apoptotic,regulated cell death characterized by iron dependency and lipid peroxidation,is involved in many pathological conditions such as neurodegenerative diseases,heart ischemia/reperfusion injury,acute renal failure,and *** metabolic dysfunctions can lead to excessive lipid peroxidation culminating in ferroptotic cell death,glutathione peroxidase 4(GPX4)resides in the center of a network that functions to prevent lipid hydroperoxides from accumulation,thereby suppressing ***,RSL3 and other small-molecule GPX4 inhibitors can induce ferroptosis in not only cultured cancer cells but also tumor xenografts implanted in ***,erastin and other system Xc−inhibitors can deplete intracellular glutathione required for GPX4 function,leading to lipid peroxidation and *** therapy-resistant cancer cells are sensitive to GPX4-targeted therapeutic regimens,the agents capable of inducing ferroptosis hold great promises to improve current cancer *** review will outline the molecular basis of ferroptosis,but focus on the strategies and the agents developed in recent years for therapeutic induction of *** potentials of these ferroptosis-inducing agents,which include system Xc−inhibitors,GPX4 inhibitors,and iron-based nanoparticles,in cancer therapy will be subsequently discussed.